Lasa Supergenerics Ltd
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.[1]
- Market Cap ₹ 135 Cr.
- Current Price ₹ 27.0
- High / Low ₹ 41.2 / 19.0
- Stock P/E
- Book Value ₹ 19.3
- Dividend Yield 0.00 %
- ROCE -6.45 %
- ROE -13.2 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -9.25% over past five years.
- Company has a low return on equity of -7.70% over last 3 years.
- Promoter holding has decreased over last 3 years: -10.8%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|
0 | 199 | 244 | 170 | 167 | 201 | 137 | 130 | 104 | 105 | |
0 | 153 | 202 | 158 | 137 | 154 | 120 | 136 | 102 | 105 | |
Operating Profit | 0 | 46 | 41 | 11 | 30 | 47 | 16 | -6 | 2 | -0 |
OPM % | 23% | 17% | 7% | 18% | 24% | 12% | -5% | 2% | -0% | |
0 | -24 | 3 | 0 | 0 | 0 | -8 | -18 | -9 | -9 | |
Interest | 0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 | 2 |
Depreciation | 0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 11 | 11 |
Profit before tax | 0 | 2 | 15 | -16 | 5 | 30 | -6 | -42 | -19 | -22 |
Tax % | -10% | 19% | -25% | 23% | 23% | -13% | -9% | 14% | ||
0 | 2 | 12 | -12 | 4 | 23 | -5 | -39 | -22 | -20 | |
EPS in Rs | 5.40 | -5.26 | 0.89 | 5.60 | -1.31 | -7.71 | -4.34 | -3.88 | ||
Dividend Payout % | 0% | 0% | 0% | 0% | 4% | -24% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -9% |
3 Years: | -20% |
TTM: | -20% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -4% |
3 Years: | % |
TTM: | -18% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | -28% |
1 Year: | -1% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -1% |
3 Years: | -8% |
Last Year: | -13% |
Balance Sheet
Figures in Rs. Crores
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0 | 0 | 23 | 23 | 41 | 41 | 50 | 50 | 50 |
Reserves | 0 | 75 | 94 | 82 | 101 | 118 | 108 | 68 | 47 |
0 | 116 | 107 | 85 | 48 | 19 | 20 | 22 | 22 | |
0 | 37 | 63 | 69 | 42 | 29 | 31 | 24 | 32 | |
Total Liabilities | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 |
0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 110 | |
CWIP | 0 | 30 | 7 | 7 | 0 | 0 | 5 | 5 | 3 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
0 | 80 | 110 | 90 | 80 | 65 | 67 | 40 | 39 | |
Total Assets | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 |
Cash Flows
Figures in Rs. Crores
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
0 | -3 | 40 | 41 | 14 | 41 | 9 | -17 | 2 | |
0 | 0 | -44 | -7 | -2 | -4 | -3 | 11 | -0 | |
0 | 0 | 4 | -33 | -10 | -36 | -0 | -4 | -2 | |
Net Cash Flow | 0 | -3 | 0 | -0 | 2 | 1 | 6 | -10 | -0 |
Ratios
Figures in Rs. Crores
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 64 | 63 | 62 | 45 | 27 | 50 | 7 | 13 | |
Inventory Days | 93 | 90 | 90 | 101 | 56 | 46 | 48 | 92 | |
Days Payable | 71 | 102 | 170 | 130 | 41 | 68 | 32 | 68 | |
Cash Conversion Cycle | 87 | 51 | -18 | 16 | 42 | 28 | 22 | 37 | |
Working Capital Days | 58 | 44 | -2 | 31 | 35 | 12 | 45 | 34 | |
ROCE % | 42% | 13% | -4% | 7% | 17% | 1% | -12% | -6% |
Documents
Announcements
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
30 Sep - Consolidated voting results of 9th AGM approved.
- Closure of Trading Window 30 Sep
- Shareholder Meeting / Postal Ballot-Outcome of AGM 27 Sep
-
Intimiation Under Regulation 30 Of SEBI (LODR), Regulation, 2015 For Grant A Patent
13 Sep - Company granted patent for 5-Chloro-2-Nitroaniline process.
-
Newspaper Advertisement - Public Notice To Members Regarding 09Thannual General Meeting
4 Sep - Public notice for 9th Annual General Meeting on September 27, 2024.
Annual reports
Concalls
-
Aug 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptNotesPPT
-
Jun 2020Transcript PPT
-
Jun 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Dec 2017Transcript PPT
Business Overview:[1]
LSL is a part of Lasa group which is a veterinary API manufacturing entity. It specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary APIs with one of the largest production capabilities in India. It covers entire animal and human healthcare value chain—from discovery-to-delivery, in research, manufacturing and global marketing. Company has backward integrated its key molecules—from discovery research up to full-scale bulk production